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Fundamentals of Care for Uveitis International Consensus Group*
Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommen-
dations for the treatment of noninfectious uveitis in the era of biologics.
Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered
practice patterns for the management of noninfectious uveitis. Current guidelines are insufﬁcient to assure
optimal use of noncorticosteroid systemic immunomodulatory agents.
Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthal-
mologists and rheumatologists) identiﬁedclinical questionsand, togetherwith6bibliographic fellows trained inuveitis,
conducted a Preferred Reporting Items for Systematic Reviews andMeta-Analyses protocol systematic review of the
literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane li-
brary, EMBASE,CINAHL,SCOPUS,BIOSIS, andWebofScience). Publications included randomizedcontrolled trials,
prospective and retrospective studies with sufﬁcient follow-up, case series with 15 cases or more, peer-reviewed
articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated
among130 international uveitis experts for review.A total of 44globally representativegroupmembersmet in late2016
to reﬁne these guidelines using a modiﬁed Delphi technique and assigned Oxford levels of evidence.
Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering
the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and
nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select
agents based on individual efﬁcacy and safety proﬁles; and evidence in speciﬁc uveitic conditions. Shared
decision-making, communication among providers and safety monitoring also were addressed as part of the
recommendations. Pharmacoeconomic considerations were not addressed.
Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and prac-
tical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients
with noninfectious uveitis with noncorticosteroid immunomodulatory agents. Ophthalmology 2018;125:757-
773 ª 2018 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.Uveitis is one of the leading causes of vision loss, and
patients are at a high risk of ocular complications, including
glaucoma, macular edema, and cataract.1e14 Recurring
ﬂares may lead to cumulative eye damage and increasing
risk of impaired vision or blindness, with the associated
patient, societal, and economic burdens.1e14 Despite pre-
dictable and serious side effects associated with long-term
use, often at high doses, oral corticosteroids remain aª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.mainstay of treatment for noninfectious uveitis (NIU).8,14e18
Local (periocular or intravitreal) corticosteroid injections
may limit systemic effects; however, they are also associ-
ated with local adverse effects such as elevated intraocular
pressure, glaucoma, and cataract.7e9,12,13
Consensus guidelines for systemic treatment of NIU were
published last in 2000, reﬂected the opinions of only 12
United States physicians, and predated the use of biologic757https://doi.org/10.1016/j.ophtha.2017.11.017
ISSN 0161-6420/17
Ophthalmology Volume 125, Number 5, May 2018therapy.16 More recent nonsystematic reviews related to
efﬁcacy of biologics and the care of patients receiving
immunosuppressants deliver more contemporaneous
guidance.19,20 Although few treatments have been approved
for the indication of uveitis treatment by governing bodies,
treatment with biologic and other systemic noncorticosteroid
immunomodulatory agents has become widespread in pa-
tients whose uveitis is not controlled with corticosteroids
alone. Furthermore, the Multicenter Uveitis Steroid Treat-
ment Trial 7-year follow-up study demonstrated that systemic
therapy (corticosteroid-supplemented immunomodulatory
therapy and biologics) improved visual outcomes, controlled
inﬂammation, and reduced macular edema compared with an
intravitreous ﬂuocinolone acetonide implant in patients with
intermediate uveitis, posterior uveitis, or panuveitis.21
Therefore, new evidence-based guidelines are needed to
facilitate a move toward optimized treatment by ophthal-
mologists and others in the care of patients with NIU.
Herein we report the outcomes of the Fundamentals of
Care for UveitiS (FOCUS) global initiative organized to
achieve consensus through evidence synthesis on optimal
systemic treatment of patients with NIU. The primary output
of this expert-led initiative was to disseminate clear, relevant,
evidence-based, and practical information for systemic ther-
apy for clinicians managing uveitis in daily practice. This
work did not look to provide consensus-management algo-
rithms, including the use of depot corticosteroids, nor were
pharmacoeconomic issues addressed in the analysis. Three
principal areas of clinical focus were considered to support
understanding and to address clinical guidance and evidence
gaps effectively: (1) optimal timing for treatment escalation
in relation to cycles of treatment in-class before moving to a
new treatment class, recognizing treatment success and fail-
ure, and identifying patients for step-up therapy; (2) tran-
sitioning treatment to a noncorticosteroid immunomodulator
or immunomodulatory agent, including biologic agents in
relation to what treatment to choose, which to exclude, and
why; when to initiate this treatment; the appropriate dosing
strategies; and how best to monitor against treatment goals
(including measures of disease activity and treatment
response and monitoring timeframes); and (3) multidisci-
plinary team collaboration in relation to management, treat-
ment plans, and decisions and for patient safety and shared
treatment goals across the multidisciplinary team.Methods
An international steering committee (ISC) comprising 9 interna-
tional experts in uveitis, including 7 ophthalmologists and 2
rheumatologists, was convened by AbbVie, Inc (AbbVie Inc,
North Chicago, IL) to deﬁne the clinical care gap and areas of
clinical focus. In addition, 130 uveitis specialists, including
thought-leading ophthalmologists and rheumatologists involved in
local professional societies or guideline committees from 28
countries with a commitment to improving standards of patient
care in their countries, were selected with guidance from the ISC
through the network of AbbVie local afﬁliates to act as national
faculties and to provide input at the local level. There was no
AbbVie involvement in the methodology, data collection and
analysis, or completion of this report.758In total, 57 draft clinical questions were developed by the ISC
to align with each of the 3 identiﬁed areas of clinical focus. The
national faculty members subsequently ranked these questions by
clinical importance. Sixteen questions of highest importance were
discussed by the ISC and were reﬁned into 9 ﬁnal questions. Six
clinical uveitis fellows (E.C., N.H., S.B.-S., S.S., J.S., L.R.S.) were
nominated by ISC members to conduct detailed literature searches
and to assess the evidence relating to each question in concert with
members of the ISC.
Eligibility Criteria for Considering Studies for
This Review
A transparent, rigorous, and clearly deﬁned literature-search
methodology was deﬁned, building on the process ﬁrst outlined
by the Standardization of Uveitis Nomenclature Working Group,1
using a Preferred Reporting Items for Systematic Reviews and
Meta-Analyses protocol.22
Search Methods for Identifying Studies
The literature search process to support the consensus statement
development and agreement is shown in Appendix 1 (available at
www.aaojournal.org), and additional methodologic details are
provided in Appendix 2 (available at www.aaojournal.org). In
brief, a systematic review of English-language publications from
January 1996 through August 2016 was performed.
Study Selection
Identiﬁed publications were reviewed further, and in some cases,
older studies were included in the analysis if they contained data of
signiﬁcance. More recent publications are cited herein, but were
excluded from consensus recommendations because they were not
included in the summary of evidence reviewed before the
consensus meeting in November 2016.
Data Collection and Risk of Bias Assessment
The quality of evidence was deﬁned using the Oxford Centre for
Evidence-Based Medicine levels of evidence criteria grading.23
Answers were developed based on the literature searches and
were documented for each clinical question using standardized
opinion-based language to avoid creating recommendations. A
note was made if the evidence level could not be substantiated
fully.
Data Synthesis and Analysis
Preliminary evidence statements that initially were developed by
the ISC and bibliographic fellows underwent a rigorous discussion
process by 27 national faculties in local meetings. The ISC
reviewed several hundred detailed comments and incorporated key
points into the ﬁnal proposed evidence statements wherever
possible. Finally, the ISC, bibliographic fellows, and representa-
tives from the national faculties met in November 2016 (in Lon-
don, United Kingdom) to reﬁne and discuss the ﬁnal statements. A
modiﬁed Delphi technique process was used to reach consensus on
the ﬁnal evidence statements associated with the agreed deﬁnitive
clinical questions. The voting system and ﬂow used to reach
consensus are shown in Appendices 3 and 4, respectively
(available at www.aaojournal.org).
Results
During the international consensus meeting, the ﬁnal 10 clinical
questions were discussed, updated, and summarized according to
Table 1. Indications for Initiating Systemic Therapy
Ocular and anatomic
Onset and course as deﬁned by SUN Working Group criteria
Acute disease that is sight threatening24e26
Chronic persistent inﬂammation20,25,27e32
Exudative retinal detachment33,34
Posterior and macular involvement35e37
Binocular sight-threatening disease20,25,27,31,33,36
Therapeutic
Regional failure to respond to:20,24,27e31,33,35,36,38e42
Periocular steroid injections42
Topical corticosteroids in JIA-associated uveitis30,41
Systemic failure20,24,25,27e30,36,37,40e53
Active uveitis while taking doses of 30 mg or 0.5 mg/kg prednisone
per day or more54
Relapse of uveitis after reduction of the oral corticosteroid dose to
less than 7 to 10 mg/day prednisone34,49,55,56
Steroid intolerance20,24e26,28e30,34,36,40,44,47,48,51,57
Need for steroid-sparing effect20,25,28,29,31,34,35,39,41,48,49,51,55,56
Severity (in adults)20,24,25,28,29,33e36,39e42,55,57,58
Visual acuity worse than 20/100 (18)34
Increase in vitreous haze of grade 234,55
Relapse of cystoid macular edema34
Disease that impacts quality of life59,60
Severity (in JIA) includes prognostic factors for visual loss,
such as:28,29,38,50,51,54,56e58,61e65
Poorer presenting visual acuity
Posterior uveitis
Uveitic complications of glaucoma
Advanced cataract
Macular edema
Synechiae
Severe band keratopathy
Ocular hypotony
Rubeosis iridis
JIA ¼ juvenile idiopathic arthritis; SUN ¼ Standardization of Uveitis
Nomenclature.
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www.aaojournal.org). Although the original scope of the analysis
included only nonanterior NIU, limited information was available
when the searches were restricted, and much of the evidence was
more broadly applicable. Consequently, most of the statements
apply generally to NIU; data that apply to a speciﬁc type of
uveitis are speciﬁed below.
Focus Area 1: Optimal Timing for Treatment
Escalation
Question 1. Which Factors Determine When Any Form of
Noncorticosteroid Systemic Immunomodulatory Therapy
Should Be Introduced into the Management of Noninfectious
Uveitis? Statement 1: Noncorticosteroid systemic immunomodu-
latory therapy (NCSIT) may be introduced for the management of
NIU to control persistent or severe inﬂammation or to prevent
ocular structural complications that present a risk to visual func-
tion. Indications for introducing NCSIT also include contraindi-
cations or intolerance to other therapies or a need for
corticosteroid-sparing effect to maintain disease remission.
Biologic therapy generally is considered for patients whose disease
is inadequately controlled by standard (corticosteroids and NCSIT)
drug therapy (evidence level [EL] 4). Grade C recommendation.
Statement 2: Indicators of severe inﬂammation include impair-
ment of visual function, bilateral disease, vitreous haze, macular or
optic nerve disease, retinal vascular inﬂammation, macular edema,
exudative detachment, or ocular structural complications that
threaten visual function. Recurrent or chronic disease may be
considered as severe disease. Associated systemic disease also may
inﬂuence the treatment approach (EL 4). Grade C recommendation.
Indications for the introduction of NCSIT in the management of
noninfectious adult uveitis can be either the uveitis type and
severity or therapeutic needs (Table 1). Although macular edema is
a common cause of visual loss in NIU43,44 and the most common
cause of moderate visual loss,45 few studies have deﬁned a
diagnosis of macular edema as an independent indicator for
starting NCSIT. There was a signiﬁcant association of central
macular thickening of 240 mm or more on OCT with worse
vision in the Multicenter Uveitis Steroid Treatment Trial.46
Therapeutic indications forNCSITmost commonly include failure
of regional corticosteroids24,27e29,33,35,36,38,39 or systemic cortico-
steroids.20,24e33,35,36,38e40,47,48,57,61e63,66,67 Lack of tolerance to
corticosteroids is a prominent reason for systemic noncorticosteroid
therapy20,26,29,30,34,40,48,57 or need for corticosteroid-sparing
effect.20,29,35,41,48,49,55 Other indications for the use of NCSIT may
include disease that severely impairs essential activities of daily living
and, consequently, quality of life.59,60
Contraindications to corticosteroid therapy include behavioral
patterns (noncompliance), health-related factors (e.g., history of
tuberculosis or hepatitis), and reproductive status (Appendix 6,
available at www.aaojournal.org). It should be noted that these
contraindications should be evaluated within the context of the
overall beneﬁt versus the risk of any therapy.68
Question 2. What Are the Essential Data and Clinical
Information That Should Be Collected about Patients before
Deciding on Noncorticosteroid Systemic Immunomodulatory
Therapy for Noninfectious Uveitis? Statement 1: Collection of
historical, laboratory, and clinically relevant nonocular imaging
data should take place before initiation of NCSIT for the treatment
of NIU. These data are used to assess baseline vital organ system
functions and to test for active or latent infectious diseases (EL 4).
Grade C recommendation.
Statement 2: Support for pretreatment testing in NIU patients
can be derived from experience with nonuveitic diseases that are
treated with NCSIT (EL 4). Grade C recommendation.Before deciding on NCSIT, it is recommended (grade C
recommendation) that clinicians should determine baseline vital
organ function and screen for infectious diseases that may be
reactivated or exacerbated by immunosuppression. In addition,
age, exposure to immunosuppressive therapy, and a family history
of malignancy may be associated with a greater risk of malig-
nancy.69 However, it should be noted that positive and negative
predictive values of screening tests used depend on the accuracy
of the diagnostic test, the pretreatment prevalence of the
abnormality in uveitis patients, and the frequency of emergent
disease during treatment. History of malignancy or testing for
tuberculosis or human immunodeﬁciency virus is important
before initiating biologic therapy. Published after the literature
review process, Wakeﬁeld et al19 formulated expert guidelines on
the assessment of uveitis patients before initiating NCSIT,
including both biologic and nonbiologic immunomodulatory
therapy, which also may provide useful guidance. In addition,
using or adapting screening procedures as they are performed in
inﬂammatory disorders, such as rheumatoid arthritis, ankylosing
spondylitis (AS), psoriasis, psoriatic arthritis (PsA), ulcerative
colitis, and Crohn’s disease, may support decision making in
NIU.70
Question 3. What Are the Clinical Criteria Used When
Deciding to Adjust Systemic Therapy? Statement: There is
signiﬁcant heterogeneity regarding the criteria used to judge759
Table 2. Management of Patients with an Inadequate Response to
Noncorticosteroid Systemic Immunomodulatory Therapy
Considerations for Management of Patients with an Inadequate Response
to Noncorticosteroid Systemic Immunomodulatory Therapy
1. Consider differential diagnosis
2A. Dose escalation of current therapy
2B. Transition to alternative noncorticosteroid systemic agent
2C. Local or regional therapies
2D. Nonmedical therapy (vitrectomy, cryotherapy, etc.)
2E. Biologic therapy
3. Therapies should be individualized based on history, cause of uveitis, and
patient preference
Currently limited evidence exists to support adding an additional agent;
safety and cost implications should be considered.
Ophthalmology Volume 125, Number 5, May 2018disease activity in NIU, but deterioration (or lack of response) in
measures of visual function, anterior chamber cells, anterior
chamber ﬂare, vitreous haze, chorioretinal lesions, retinal vascular
lesions, or macular or optic nerve involvement are among the pa-
rameters that can be inﬂuential in decisions to adjust therapy
(EL 4). The overall level of evidence supporting criteria used to
assess disease activity and adjusting of systemic therapy (including
withdrawal of therapy) support a grade B/C recommendation.
Although there is considerable heterogeneity,20,31,33,35,49,71
clinical criteria with the strongest evidence supporting their use-
fulness in adjusting systemic therapy (where the eye is the major
organ affected in systemic disease and decisions are led by the
ophthalmologist) are visual acuity (VA) and ocular inﬂammation,
as deﬁned by Standardization of Uveitis Nomenclature Working
Group criteria.1 A recent Delphi panel developed the Uveitis
Disease Activity Index to assess global ocular inﬂammatory
activity in patients with uveitis;72 however, this has not yet been
validated as a method to assess the need for therapeutic
adjustment. Given that uveitides comprise several distinct
diseases, assessments that are more speciﬁc to different forms of
disease also may be desirable.
Question 4A. If the Noncorticosteroid Systemic Immuno-
modulatory Agent Is Not Adequately Effective, What Should Be
Considered First? Statement: Treatment nonadherence, infections,
and masquerade syndromes must be considered in any patient with
NIU before a change in therapy is considered (EL 3A). Grade B
recommendation.
The goal of treatment in uveitis must be to suppress ocular
inﬂammation and achieve inactive disease state or drug-induced
remission. In any patient who is not beneﬁting adequately from
immunomodulatory therapy, deﬁned according to the Standardi-
zation of Uveitis Nomenclature Working Group criteria as either a
2-step increase in the level of inﬂammation or an increase to the
maximum grade (worsening) or as a lack of 2-step decrease in the
level of inﬂammation and inability to decrease to inactive disease
despite therapy,1 the diagnosis should be reconsidered (Table 2),
with special attention paid to the possible role of infection,
masquerade, or patient nonadherence. Masquerade syndrome
represents the presence of a condition, such as intraocular
malignancy or retinal degeneration, which may mimic
inﬂammation. The incidence has been suggested to be as high as
2.5% of cases of NIU in a tertiary referral clinic.73 Appropriate
diagnosis for malignancy, such as lymphoma, could include
diagnostic vitrectomy, cerebrospinal ﬂuid for cytologic analysis,
and brain imaging by magnetic resonance imaging. The
differential diagnosis for inﬂammation not responsive to
corticosteroids and immunomodulatory therapy also includes
infections, such as syphilis, tuberculosis, and a variety of viral
causes.
Question 4B. If the Noncorticosteroid Systemic Immuno-
modulatory Agent Is Not Adequately Effective or Adequately
Tolerated, What Should the Next Approach Be? Statement 1:
Dose escalation of the NCSIT to the maximum tolerated thera-
peutic dose may be considered before introducing an alternative
medication (including introduction of a biologic agent) or other
approach in the management of NIU (EL 2A; see Appendix 7 for
supporting evidence, available at www.aaojournal.org). Grade B
recommendation.
Statement 2: Patients with NIU may be transitioned to an
alternative or additional agent (EL 1B; see Appendix 7 for
supporting evidence) if the initial NCSIT is controlling the
disease inadequately. Grade A recommendation.
Statement 3: Therapy choice for patients with NIU that is
refractory to NCSIT must be individualized based on multiple
factors, including the patient’s history, underlying cause of uveitis,760other systemic comorbidities, or a combination thereof (EL 4; see
Appendix 7 for supporting evidence). Grade C recommendation.
Optimizing the dosage of the noncorticosteroid systemic agent
often is the ﬁrst option before introducing a novel medication or
approach. Escalating the dose can increase efﬁcacy and may be
tried in an individual patient, especially given variability in
absorption and metabolism. Patients may be transitioned to an
alternative agent if the initial NCSIT is not working or there are
other reasons for discontinuing (EL 1B). For example, this may be
from mycophenolate to methotrexate, or vice versa. There are
limited published data to support adding another agent, and the
safety and cost implications should be considered with this
approach.
Nonmedical or surgical treatment in some cases may be
considered as a primary option, particularly in cases where NCSIT
is ineffective (EL 4). Pars plana vitrectomy has been studied as a
surgical treatment option in patients with persistent inﬂammation
and macular edema.74 Peripheral cryotherapy represents another
surgical treatment option, especially for active pars planitis. It
should be noted that surgical interventions can have late
sequelae, such as cataractogenesis.75,76 In addition, because the
surgery does not address the underlying immune-mediated cause of
the inﬂammation, many experts regard the intervention as likely to
be of temporary beneﬁt.
Patients’ understanding of their ocular disease process often
is incomplete, which may inﬂuence adherence to therapy.77
Although a dearth of information exists on factors inﬂuencing
patient adherence in uveitis therapy, this must be an important
consideration in any patient who fails to improve with
noncorticosteroid systemic therapy (EL 3A). The ultimate choice
for therapy must be individualized based on multiple factors,
such as the patient’s history (e.g., history of hepatitis),
underlying cause of uveitis, patient preference, cost, and
convenience (EL 4).
Question 5. When Should Noncorticosteroid Systemic
Immunomodulatory Therapy Be Withdrawn? Statement: The
decision to withdraw NCSIT for NIU should be individualized
based on shared decision making that incorporates considerations
such as patient preference, tolerance of and risk resulting from the
current treatment, duration of disease control, and the speciﬁc
cause of uveitis (EL 4; see Appendix 7 for supporting evidence).
Grade C recommendation.
Inadequate clinical response is cited as the most frequent cause
for discontinuation of therapy, followed by inefﬁcacy (no clinical
drug effect noted), then adverse drug reactions (EL 2A).78 Cost and
desire for fertility are also considerations, and all of these factors
can be used to guide withdrawal decisions.79 Although the data
on sustained remission after withdrawal of biologic therapy are
Dick et al  Noncorticosteroid Therapy for Noninfectious Uveitislimited, there are some supportive data in juvenile idiopathic
arthritis and even more limited data from Behçet’s disease
(EL 3A).80e85
Any decision to withdraw systemic therapy in patients achieving
remission involves a classic riskebeneﬁt analysis that considers the
risk that the inﬂammation will recur and the beneﬁts resulting from
not being subjected to systemic immunosuppression. A discussion
about when to withdraw NCSIT also frequently arises in other
conditions, such as organ transplantation or rheumatic diseases. We
hesitate to extrapolate these observations directly to uveitis because
prognosis and disease course vary greatly and because the potential
for irreversible structural damage arguably is greater with intraoc-
ular inﬂammation. The decision to withdraw systemic therapy must
be individualized based on shared decision making that incorporates
considerations such as patient and physician preference, tolerance of
and risk resulting from the current treatment, disease severity, and
the speciﬁc cause of uveitis (EL 4).
Focus Area 2: Transitioning Treatment to
Noncorticosteroid Systemic
Immunomodulatory Therapy, Including
Biologics
Question 6. What Evidence Is Available to Guide the Selection
of Noncorticosteroid Systemic Immunomodulatory Therapy for
Noninfectious Uveitis, Excluding Biologics? Statement: Effective
noncorticosteroid, nonbiologic immunomodulatory therapies for
the treatment of NIU include mycophenolate mofetil (EL 2B),
tacrolimus (EL 2B), cyclosporine (EL 2B), azathioprine (EL 2B),
and methotrexate (EL 2B). Grade B recommendation (see
Appendix 7 for supporting evidence).
A number of agents have been evaluated for treating NIU
(Table 3). Although many studies did not distinguish between
different subtypes and causes of uveitis, data for the most
commonly studied and used agents are described below,
including mycophenolate preparations, tacrolimus, cyclosporine,
azathioprine, and methotrexate. Other agents, such as
chlorambucil,86 cyclophosphamide,87,88 and leﬂunomide have
been used. However, the level and amount of evidence are limited
and do not meet the criteria for this report. There is limited
evidence of beneﬁt from local therapies, such as intravitreal
sirolimus89e92 and methotrexate,93 as an alternative treatment
strategy in NIU. However, there is no evidence comparing
outcomes for these local therapies with systemic
noncorticosteroid therapy (overall grade C recommendation for
local sirolimus and methotrexate). Intravitreal sirolimus may be
moderately effective in reducing inﬂammation and is associated
with low risk of adverse events (AEs) in patients with active
NIU.89e92
Mycophenolate Preparations. Evidence of inﬂammation
control, steroid-sparing effect, and VA improvement in most
patients supports a grade B recommendation for mycophenolate
mofetil for NIU (Table 3). The evidence for other mycophenolate
preparations is not robust (EL 4) and supports a grade C
recommendation. Overall, mycophenolate preparations generally
were well tolerated, with low rates of discontinuation resulting
from AEs.94e96
Mycophenolate preparations also have demonstrated moderate
efﬁcacy alone97 and in combination with cyclosporine98 for
control of birdshot chorioretinopathy. The grade C
recommendation for the use of mycophenolate derivatives (alone
or with cyclosporine) reﬂects the low-level evidence for this
drug combination. Mycophenolate mofetil also has been evaluated
in acute Vogt-Koyanagi-Harada (VKH) disease,99 and in acomparative study (vs. methotrexate) in patients with acute or
chronic VKH disease100 in combination with high-dose oral
corticosteroids. These studies support the use of mycophenolate
mofetil and methotrexate for control of inﬂammation and main-
tenance of VA, with no evidence of superiority of one drug over
the other (grade C recommendation).
Calcineurin Inhibitors: Tacrolimus and Cyclo-
sporine. There is some evidence to support the efﬁcacy of the
calcineurin inhibitors tacrolimus and cyclosporine (EL 2B) for
control of inﬂammation in NIU as well as improvements in
VA,101e104 supporting a grade B recommendation. Similar effects
were seen in improvements in VA with tacrolimus and cyclo-
sporine. However, tacrolimus may be slightly better tolerated
versus cyclosporine (6% vs. 37% of patients reported AEs), and
discontinuations were lower.103
Azathioprine. Azathioprine as a single agent alongside
corticosteroids demonstrated control of inﬂammation and
corticosteroid-sparing outcomes in patients with intermediate and
posterior uveitis and panuveitis. However, there is a lack of
evidence for improvement in visual outcomes.105,106 In one study,
approximately 17% of patients discontinued therapy because of
ineffectiveness and 24% stopped therapy because of AEs within
the ﬁrst year,106 although a second study did not report
discontinuations because of AEs,105 demonstrating moderate
efﬁcacy for azathioprine in NIU (grade B recommendation).
Azathioprine demonstrated moderate efﬁcacy in inﬂammation
control and a signiﬁcant steroid-sparing effect in patients with
severe uveitis secondary to Behçet’s disease.55 Therapy was well
tolerated, with only 2% of patients discontinuing therapy.
Azathioprine also has been evaluated in patients with acute and
chronic VKH disease (alongside high-dose steroids in the acute
phase) and demonstrated control of inﬂammation (85.5% in acute
VKH disease and 90% in chronic VKH disease), with a median
time to steroid-sparing effect of 4 months.107 However, this single
study in a small cohort of patients (n ¼ 16) constitutes low-level
evidence (EL 4).
Methotrexate. Evidence from 2 studies demonstrates the
efﬁcacy of methotrexate in inﬂammation control, steroid-sparing
ability, and maintenance and improvements of VA in patients
with NIU47,108 and supports a grade B recommendation for
methotrexate in NIU.
Comparative Studies of Antimetabolites (Mycophenolate
Mofetil, Azathioprine, and Methotrexate). Comparative studies
of antimetabolites demonstrate moderate support for efﬁcacy of
methotrexate and mycophenolate mofetil in steroid-sparing control
of NIU (overall grade C recommendation),71,109 with no signiﬁcant
differences in uveitis control among these drugs. Rates of side
effects, laboratory test complications, and discontinuation of ther-
apy were reported to be higher with azathioprine compared with
mycophenolate mofetil and methotrexate.110
Question 7. Which Biologic Should Be Used for the Treat-
ment of Noninfectious Uveitis? Statement 1: The use of adali-
mumab for the treatment of NIU is supported (EL 1B; see Appendix
7 for supporting evidence). Grade A recommendation.
Statement 2: The use of inﬂiximab for the treatment of NIU is
supported (EL 2B; see Appendix 7 for supporting evidence). Grade
B/C recommendation.
Statement 3: There is no evidence to support the use of eta-
nercept in NIU (EL 2B). Grade B recommendation.
Statement 4: The use of subcutaneous secukinumab in non-
anterior NIU is not supported (EL 2B). Grade B recommendation.
Statement 5: The use of interferon alfa-2a in nonanterior NIU is
supported (EL 2B). There is limited evidence to support the use of
pegylated interferon alfa in nonanterior NIU in patients with
Behçet’s disease (EL 2B). Interferon b demonstrated efﬁcacy in the761
Table 3. Evidence for Individual Systemic Noncorticosteroid Immunomodulatory Therapy Agents and Disease-Speciﬁc Recommendations
Drug No. of Studies*
Disease Anatomic
Locationsy Disease Entities or Cause
Outcomes
Evidence Level
Recommendation
Level
Inﬂammation
Control
Visual Acuity Stability or
Improvement Steroid Sparing
Mycophenolate
preparationsz
13 Anterior uveitis,
intermediate uveitis,
posterior uveitis, and
panuveitis
NIU Yes Yes Yes 2Bx Bx
BCR Yes No Yesk 2B/3 C
VKH disease Yes Yes Yes{ 2B/3 C
Azathioprine** 4 Anterior uveitis,
intermediate uveitis,
posterior uveitis, and
panuveitis
NIU Yes No Yes 2B C
BD Yes Yes Yes 2B B
VKH disease Yes No Yes 4 C
Methotrexateyy 5 Anterior uveitis,
intermediate uveitis,
posterior uveitis, and
panuveitis
NIU Yes Yes Yes 2B B
VKH disease Yes Yes Yes 2B/3 C
Cyclophosphamide 2 Anterior, intermediate,
and posterior uveitis
NIU Yeszz No Yeszz 4 C
Calcineurin inhibitors:
tacrolimus/
cyclosporine
4 Anterior uveitis,
intermediate uveitis,
posterior uveitis, and
panuveitis
NIU Yes Yes Yes 2B B
Chlorambucil 1 Panuveitis Sympathetic ophthalmia Yes Yes Yes 4 C
Evidence for
noncorticosteroid
local therapy
Methotrexate 1 Anterior uveitis,
intermediate uveitis,
and panuveitis
NIU Yes No 4 C
Sirolimus 4 Intermediate uveitis,
posterior uveitis, and
panuveitis
NIU Yes Yes Yes 2B C
BCR ¼ birdshot chorioretinopathy; BD ¼ Behçet’s disease; NIU ¼ noninfectious uveitis; VKH ¼ Vogt-Koyanagi-Harada.
*Some older studies identiﬁed in the literature search were excluded based on quality of reporting, consistency in reporting steroid-sparing effect (prednisone 10 mg), use of Standardization of Uveitis
Nomenclature criteria, and adherence to Standardization of Uveitis Nomenclature criteria for reporting improvement or failure to improve.
yData are consolidation of all anatomic locations covered in the associated publications. Some publications may cover some anatomic locations and some may cover others.
zSeven studies with mycophenolate mofetil, 1 study with mycophenolate sodium, and 1 study in combination with cyclosporine; 2 studies in BCR; and 2 in VKH disease, including 1 study with methotrexate
as comparator (no evidence of superiority of either drug) and 1 with methotrexate and azathioprine as comparators.
xEvidence level 4 and grade C recommendation for mycophenolate sodium.
kData not available for combination with cyclosporine.
{One hundred percent steroid-sparing control of inﬂammation with mycophenolate mofetil alone.
**Includes study with mycophenolate mofetil and methotrexate as comparators.
yyIncludes 1 study with methotrexate and mycophenolate mofetil as comparators and 1 study in VKH disease with mycophenolate mofetil as comparator.
zzOne study reported only on the entire cohort and not on uveitis patients within the cohort.
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Dick et al  Noncorticosteroid Therapy for Noninfectious Uveitistreatment of pars planitis in a small pilot randomized controlled
trial (RCT; EL 2B). Grade B recommendation.
Several biologic therapies have been evaluated for the man-
agement of NIU across uveitis subtypes, disease causes, and
anatomic locations, with the level of evidence varying consider-
ably. Data on the most commonly used biologics are described
below, with a comprehensive list in Table 4.
Adalimumab. Adalimumab is recommended for the treatment
of nonanterior NIU in adults (grade A recommendation). Evidence
supporting the use of adalimumab for the treatment of nonanterior NIU
in adults is derived from 2 multinational RCTs49,111 that evaluated the
efﬁcacy and safety of adalimumab in adult patients with active non-
anteriorNIUdespite high-dose corticosteroids111 andadult patientswith
inactive nonanterior NIU controlled by corticosteroids.49 In these
studies, adalimumab signiﬁcantly lowered uveitic ﬂare and loss of
VA. A further RCT evaluating adalimumab in severe forms of
nonanterior NIU in adults demonstrated that adalimumab is superior
to placebo in improving VA and reducing ﬂares.112
Adalimumab is indicated in the United States for the treatment
of noninfectious uveitis, intermediate uveitis, posterior uveitis, and
panuveitis in adult patients113 and in Europe for the treatment of
noninfectious uveitis, intermediate uveitis, posterior uveitis, and
panuveitis in adult patients who have had an inadequate response
to corticosteroids, in patients in need of corticosteroid sparing, or
in whom corticosteroid treatment is inappropriate.114 Although
adalimumab for treating anterior uveitis was not included in the
recommendation, its use in the prevention of acute anterior
uveitis was described in some of the supporting literature. For
example, it has been shown to reduce the rate of anterior uveitis
ﬂares and recurrences in AS.115e119
Further, since the consensus meeting in November 2016, data
from a randomized study, SYCAMORE,120 evaluating the efﬁcacy
of adalimumab in combination with methotrexate in juvenile
idiopathic arthritis-associated anterior uveitis have been published.
This study reported a strong beneﬁcial effect with adalimumab plus
methotrexate, with signiﬁcant relative risk reduction and delay in
time to treatment failure compared with methotrexate alone (hazard
ratio, 0.25; 95% conﬁdence interval, 0.12e0.49; P < 0.0001). A
signiﬁcant steroid-sparing effect also was observed (P¼ 0.04), with
a signiﬁcant number of patients in the adalimumab plusmethotrexate
group reducing or discontinuing topical glucocorticoids (P¼ 0.02).
Inﬂiximab. Evidence derived from prospective, non-
comparative, open-label trials supports the use of inﬂiximab for the
treatment of NIU in adults (EL 2B, 3B, and 4), particularly in
Behçet’s disease.121,122 Overall, there is moderate evidence sup-
porting the use of inﬂiximab in Behçet’s disease, pediatric NIU,123
and other uveitis entities40,124 (grade B/C).
In Behçet’s disease, inﬂiximab provided complete remission in
30% to 85.7% of patients,121,122,125e128 with a good response
(investigator opinion) in 76.7% of cases and a signiﬁcant decrease in
the number of uveitis attacks.129 There was no signiﬁcant difference
in reduction of total inﬂammatory score versus intravenous
methylprednisolone or intravitreal triamcinolone; however,
reduction in inﬂammation was more rapid with inﬂiximab (2
weeks).130 Improvements in macular edema131 and best-corrected
VA (BCVA) were statistically signiﬁcant after inﬂiximab
treatment.127,132e134 Inﬂiximab treatment also resulted in a decrease
in or discontinuation of, or both, systemic anti-inﬂammatory agents
in patients with Behçet’s-associated uveitis.127,132 Quality of life
(relief from uveitis attacks and extraocular manifestations) improved
signiﬁcantly in patients with Behçet’s disease with inﬂiximab.126
Adalimumab and Inﬂiximab in Anterior Uveitis Associated
with Ankylosing Spondylitis. Although it was not part of the
original analysis, which focused on nonanterior NIU, we believed
that it was important that information on the use of tumor necrosisfactor inhibitors in anterior uveitis be included in the manuscript
because it is the most common extra-articular manifestation in AS.
A recent meta-analysis described a cumulative incidence of
approximately 1 in 4 patients,135 and another recent study reported
acute anterior uveitis incidence in 30% to 40% of individuals with
AS, with prevalence approaching 60% in patients with AS for more
than 50 years.136 International organizations that recently issued
recommendations for the treatment of spondyloarthritis all have
suggested that adalimumab and inﬂiximab are preferred biologic
agents for treatment and prevention of uveitis as an extra-
articular manifestation of spondyloarthritis.137e140
Etanercept. There is no evidence to support the use of
etanercept in refractory nonanterior NIU (EL 2B). Etanercept 25
mg administered subcutaneously twice weekly (as monotherapy or
with methotrexate) did not provide control of ocular inﬂammation
or steroid-sparing effect when compared with placebo in 2
RCTs.141,142 There is secondary evidence, not evaluated in our
methodology, that infers etanercept may alter the rate of uveitis in
patients with spondyloarthropathy.118,119 In addition, there are also
reports of paradoxical occurrences of uveitis after etanercept
administration in patients with AS-related acute anterior uveitis.116
Secukinumab. In patients with Behçet’s disease and active
or quiescent NIU, secukinumab, dosed subcutaneously, does not
demonstrate control of ocular inﬂammation or decrease uveitis
recurrence.143 There was no signiﬁcant reduction in inﬂammatory
attacks, decrease in vitreous haze, or improvement in BCVA.143
However, intravenous dosing in patients with active,
noninfectious, nonanterior uveitis provided some control in 72.7%
of patients at 6 months as well as some steroid-sparing effect.144
Interferons. In adult NIU (including that associated with
Behçet’s disease) or other uveitis entities, interferon alfa-2a
administered subcutaneously without concomitant steroids was
effective in controlling NIU (grade B
recommendation).78,85,145e158
Interferon alfa-2a has demonstrated efﬁcacy in control of
uveitic ﬂares in patients with Behçet’s disease as well as in patients
with other uveitis entities.145e150,152e158 Relapse rate also
decreased signiﬁcantly (from 1.39e3.61 relapses/person annually
to 0.05e0.8 relapses/person annually).159 Visual acuity improved
or remained stable and resolution of macular edema was
observed in all those patients with macular edema at
baseline.85,145,148,150,152e156 Signiﬁcant reductions in mean oral
prednisolone dose also were achieved.147,148,152
There is very limited evidence to support the use of pegylated
interferon alfa for NIU (EL 2B). In one randomized study, there
was no difference from placebo in relapse rates. However, there
was a signiﬁcant steroid-sparing or immunosuppressant-sparing
effect.160
Interferon b administered subcutaneously (2 weeks at 22 mg 3
times weekly then 44 mg every 3 weeks) has demonstrated efﬁcacy
in the treatment of pars planitis in a randomized pilot study (EL 2B).
Patients showed a signiﬁcant increase in BCVA at 3 months versus
methotrexate, with mean improvement in BCVA of 0.31 logarithm
of the minimum angle of resolution versus 0.09 logarithm of the
minimum angle of resolution, respectively. Vision-related quality of
life also improved compared with those receiving methotrexate.28
Question 8. How Do You Assess Patient Safety While
Noncorticosteroid Systemic Immunomodulatory Therapy Is
Being Administered? Statement: Support for safety monitoring
while administering treatment derives from experience with uveitis
and nonuveitic diseases that are treated with NCSITs.
There was signiﬁcant variability in level of knowledge, along
with low self-ratings regarding speciﬁc indications and toxicities
for certain medications, in a survey of 51 United States ophthal-
mologists;161 therefore, we included an additional statement with763
Table 4. Evidence Supporting Use of Biologics and Recommendation
Originator Biologic No. of Studies Anatomic Location* Disease Entities or Cause
Outcomes
Evidence Level
(No. of
Publications)
Recommendation
Level
Inﬂammation
Control
Visual Acuity
Stability or
Improvement
Steroid
Sparing
Antietumor necrosis
factor
Inﬂiximab 24 Anterior, posterior, retinal
vasculitis
BD Yes Yes Yes 2B (3), 3B (2),
4 (8)
B
Anterior uveitis, intermediate
uveitis, posterior uveitis,
panuveitis
Pediatric NIU (uveitis entities
include JIA, BD, sarcoidosis,
VKH disease)
Yes Yes Yes 2B (1), 4 (2),
5 (1)
C
Anterior uveitis, intermediate
uveitis, posterior uveitis,
panuveitis
Other uveitis entities (including
BD, BCR, sarcoidosis,
idiopathic vasculitis, VKH
disease)
Yes Yes Yes 2B (2), 3B (1),
4 (4)
B
Adalimumab 15 Anterior uveitis, intermediate
uveitis, posterior uveitis,
panuveitis
NIU (including different uveitis
entities: BD, idiopathic
uveitis, sarcoidosis, BSRC,
TINU, VKH disease, pars
planitis; other: HLA-B27, JIA)
Yes Yes Yes 1B (4), 2B (4),
4 (5), 5 (2)
A
Golimumab 2 Anterior uveitis, intermediate
uveitis, posterior uveitis,
and panuveitis
NIU Yes Yes Yes 4 C
Etanercept 2 Anterior, intermediate,
posterior uveitis
NIU, sarcoidosis ✗ ✗ ✗ 2B B
Certolizumab No studies
fulﬁlling inclusion
criteria
d d d d d D
Anti-interleukin 1
Anakinra/canakinumab 1 Anterior uveitis, intermediate
uveitis, posterior uveitis,
and panuveitis
BD Yes d d 4 C
Gevokizumab 1 Posterior uveitis, panuveitis,
and/or retinal vasculitis
BD Yes d d 2B C
Anti-interleukin 2
Daclizumab 7 Anterior uveitis, intermediate
uveitis, posterior uveitis, or
panuveitis; retinal
vasculitis
NIU (including different uveitis
entities such as: idiopathic
anterior uveitis and panuveitis;
MCP; scleritis, idiopathic
panuveitis; sarcoid panuveitis;
HSV-associated anterior
scleritis; idiopathic
keratouveitis)
Yes Yes Yes 2B (5) and 4 (2) B
Anti-interleukin 6
Tocilizumab 2 Anterior uveitis, intermediate
uveitis, posterior uveitis,
and panuveitis; also note
retinal vasculitis with and
without uveitis
NIU (including different uveitis
entities)
Yes Yes ✗ 4 C
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Table 4. (Continued.)
Originator Biologic No. of Studies Anatomic Location* Disease Entities or Cause
Outcomes
Evidence Level
(No. of
Publications)
Recommendation
Level
Inﬂammation
Control
Visual Acuity
Stability or
Improvement
Steroid
Sparing
Sarilimumab Ongoing CT, no
results
NIU (including different uveitis
entities)
d d d d D
Anti-interleukin 17
Secukinumab 4 (2 publications) Intermediate uveitis, posterior
uveitis, panuveitis
NIU (including different uveitis
entities: Behçet’s uveitis
noninfectious; non-Behçet’s
uveitis; quiescent, non-
infectious, non-Behçet’s
uveitis)
Yes ✗y Yes 1B (1) and 2B (3) B
Anti-CD-20
Rituximab 1 Anterior uveitis, posterior
uveitis, and retinal
vasculitis
BD Yesz d d 2B C
AntieCD-52
Alemtuzumab 1 Not speciﬁed BD Yes d Yes 2B C
Interferons
Interferon alfa-2a
and -2b
15 Anterior uveitis, intermediate
uveitis, posterior uveitis or
panuveitis or retinal
vasculitis
BD and other uveitis entities
including pars planitis, VKH
disease, idiopathic panuveitis,
uveopapillitis
Yes Yes Yes 2B (6), 3B (1),
4 (6), 5 (2)
B
Pegylated interferon
alfa-2b
1 Nonanterior uveitis BD d d Yesx 2B C
Interferon b 1 Intermediate uveitis or uveitis
associated with multiple
sclerosis
Patients with primary
intermediate uveitis or uveitis
associated with multiple
sclerosis
Yesk Yes d 2B C
Others
Intravenous
immunoglobulins
1 Posterior uveitis BCR d Yes d 2B C
BCR ¼ birdshot chorioretinopathy; BD ¼ Behçet’s disease; BSRC ¼ birdshot retinochoroidopathy; CT ¼ clinical trial; HLA ¼ human leukocyte antigen; HSV ¼ herpes simplex virus; JIA ¼ juvenile
idiopathic arthritis; MCP ¼ multifocal choroiditis and panuveitis; NIU ¼ noninfectious uveitis; TINU ¼ tubulointerstitial nephritis and uveitis; VKH ¼ Vogt-Koyanagi-Harada; ✗ ¼ No; d ¼ no data.
*Data are consolidation of all anatomic locations covered in the associated publications. Some publications may cover some anatomical locations and some may cover others.
yNot signiﬁcant compared with placebo or different doses of secukinumab.
zNot statistically signiﬁcant in comparison with cyclophosphamide.
xIn patients who were receiving corticosteroids at baseline, the corticosteroid requirement was signiﬁcantly lower in the pegylated interferon-alfa-2b group compared with the noninterferon group.
kImprovement not signiﬁcant compared with the methotrexate arm.
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Ophthalmology Volume 125, Number 5, May 2018an emphasis on clearly addressing patient safety screening and
monitoring. It should be noted that a limitation of this statement
was that it arose from a different process to the remaining
statements and was not supported by the evidence synthesis.
Nevertheless, because it has implications across all the other
questions and statements, we considered it important to include a
statement about monitoring for adverse effects from medication.
An interdisciplinary panel of 12 uveitis specialists and rheu-
matologists convened in 2000 to outline best practices and
guidelines for use of immunosuppressive drugs, including recom-
mendations for duration of corticosteroid therapy and optimal
tapering schedules, as well as thresholds for prescribing immuno-
modulatory therapy.16 Patients should be made aware of the
systemic side effects of oral corticosteroid therapy, and blood
pressure and blood sugar should be monitored every 3 months
while receiving the medication, along with bone-mineral density
and serum-lipid monitoring.16 The panel also outlined the side
effects of different classes of immunomodulatory medications, as
well as dosages and indications, providing suggested frequencies
of laboratory monitoring.16 With the introduction and availability
of new classes of immunosuppressive agents, these
recommendations have been expanded to include biologic agents
such as tumor necrosis factor inhibitors, and place emphasis on
careful assessment of patients before commencing
immunosuppressive or biologic therapy, or both, and on
monitoring and preventing viral or bacterial infection,
cardiovascular side effects, and metabolic and bone diseases and
on reducing iatrogenic side effects in a manner no different from
their use in other disease states.19 We also recognize that
guidelines and guidance for safety screening and monitoring of
patients vary globally in relation to treatment with
noncorticosteroid immunomodulatory agents or biologics, as well
as across different disease states, and it is likely that similar
consideration to local practices may be applied in NIU.162e165
Appendix 8 (available at www.aaojournal.org) outlines
recommended monitoring and management practices associated
with treatments for NIU.
Focus Area 3: Collaboration across the
Multidisciplinary Team
Question 9. How Would You Discuss the Therapeutic Options
(Pros and Cons) and Make a Shared Decision with the Patient?
Statement: Shared decision making is an appropriate strategy in
caring for patients with NIU, but there are limited data to guide this
interaction. Discussions regarding the choice of therapy should be
tailored to ﬁt the needs and expectations of individual patients and
their healthcare professionals. Availability of information in mul-
tiple formats is desirable (EL 4). Grade C recommendation.
When reviewing treatment options with patients, it is important
to emphasize the chronic nature of uveitis as a condition requiring
ongoing treatment, during which potential adverse effects from
therapy may manifest at varying stages.166 Besteworst scaling has
been used as an estimate for patient preferences in the treatment of
uveitis in a patient survey from the Multicenter Uveitis Steroid
Treatment Trial follow-up study of patients with nonanterior NIU
and outpatients with predominantly anterior NIU at 2 United States
ocular inﬂammation subspecialty clinics. Patient outcome prefer-
ence of local versus systemic corticosteroid therapies for NIU was
evaluated,167 and not meeting vision requirements for driving,
development of glaucoma, and need for eye surgery were ranked
as more salient concerns than high blood pressure and
cholesterol, cataracts, or systemic infections by patients.167
Understanding and sharing outcomes relevant to patients may
inform them on how best to weigh the risks and beneﬁts of766therapeutic options and may provide speciﬁc markers for them to
assess the impacts of therapy on their lives.
An additional sampling of the rheumatology literature provides
further insight for shared decision making for uveitis therapy. For
example, low-literacy decision aids for rheumatoid arthritis
patients improved knowledge of the treatment while reducing
decision-making conﬂict.168 One shortcoming of the uveitis
literature regarding shared decision making is the absence of
speciﬁc metrics for deﬁning how to arrive at a decision with the
patient. The Outcome Measures in Rheumatology Clinical Trials
Working Group169 determined 7 domains for assessment of
shared decision-making: (1) identifying the decision, (2)
exchanging information, (3) clarifying views, (4) deliberating, (5)
making the decision, (6) putting the decision into practice, and (7)
assessing the effect of the decision.
It should be noted that shared decision making also can have
negative aspects,170 including impact on time, that limit the ability
to discuss each option thoroughly and the opportunity for patient
reﬂection. Individual biases also impact discussion (e.g.,
experiencing a patient having an AE could bias that provider’s
advice, and anecdotal evidence may inﬂuence a patient more
than results from a controlled study). In summary, shared
decision making in uveitis is important, and efforts should be
made to involve patients by making information relevant and
understanding their view of the impact of their treatment on their
lives.
Question 10. How Do We Ensure Effective Communication
between Internists or Rheumatologists and Ophthalmologists to
Optimize Safe Prescribing and Monitoring of Systemic Ther-
apy? Statement: Patients with uveitis may beneﬁt from the input of
more than one medical speciality. Communication among health-
care professionals fosters optimal diagnosis and therapy. The
optimal methods to enable this communication require further
investigation (EL 4). Grade C recommendation.
Communication between physicians has been identiﬁed as a
potential deﬁciency in the healthcare system. A survey of specialist
and primary care physicians revealed that a signiﬁcant number
expressed dissatisfaction with how information regarding a patient
referral was conveyed.171 Multiple cross-sectional surveys of
physicians have demonstrated that a lack of coordinated care be-
tween primary care physicians and specialists negatively impacts
patient care, and this further impacts the patientephysician rela-
tionship by reducing patient conﬁdence in their care.172
A dearth of literature exists regarding optimal communication
between ophthalmologists and rheumatologists or internists with
respect to shared monitoring of efﬁcacy and side effects. Thus,
although interdisciplinary management has near universal support,
few practical guidelines exist to help actualize this dialog.
Although it is difﬁcult to quantify its beneﬁt, the authors believe
that an interdisciplinary clinicdfor example, one that combines
rheumatologists with ophthalmologists at the same physical
locationdis an effective approach to optimize communication
among specialists. Obstacles to this communication paradigm
include the challenge to use time efﬁciently for all practitioners and
issues regarding the division of compensation for the care
provided.173
An alternative or supplementary approach is found in the
rheumatology literature, which offers some empirical guidance on
the use of biological nurse specialists for monitoring therapeutic
outcomes and safety, which may have applications for patients who
are managed between ophthalmologists and rheumatologists in an
interdisciplinary setting. The biological nurse specialist has
emerged as an important component of patient care in rheuma-
tology, assuming responsibilities such as monitoring disease-
activity metrics, training patients to self-administer subcutaneous
Dick et al  Noncorticosteroid Therapy for Noninfectious Uveitismedications, coordinating nurse specialists and consultants from
other disciplines, and managing telephone-advice helplines.174 In
addition, a Spanish Delphi consensus offered guidance on
comanagement of PsA with dermatologists,175 stating that
generally the rheumatologist manages PsA with the
dermatologist, referring to the dermatologist after detection of
worsening psoriasis. The specialists also confer on any change in
patient treatment that affects the course of PsA or psoriasis.
In summary, multidisciplinary collaboration comes in many
forms, with the beneﬁts from such interactions documented in peer-
reviewed literature. Their speciﬁc applications to the interdisci-
plinary relationship among ophthalmologists, rheumatologists, and
internists for management of uveitis need further and more speciﬁc
study in the coming years.Discussion
Noninfectious uveitides are rare, sight-threatening inﬂam-
matory diseases often associated with comorbid, systemic,
immune-mediated inﬂammatory diseases. The most
commonly used treatment options, corticosteroids, are
associated with signiﬁcant side effects, and long-term use is
not recommended to achieve the treatment goal of uveitis
quiescence. Systemic immunosuppressants generally are
used off-label as second-line therapy for patients whose
uveitis is not sufﬁciently controlled with corticosteroids.16
However, prospective, randomized, placebo-controlled tri-
als are uncommon and few treatments are approved.71,109,110
The goal of the FOCUS initiative was to support optimal
management of NIU across relevant specialties, with the
ultimate aim of improving patient outcomes. This program
included an academically rigorous process, supported by a
large number of uveitis specialists worldwide, including
both rheumatologists and ophthalmologists who collaborate
in the care of patients with NIU, and represents a broad
range of clinical opinion from diverse geographical regions
and a variety of clinical practices. Most studies on in-
terventions for uveitis include patients with diverse forms of
uveitis. However, we recognize that the therapeutic
approach for Behçet’s disease, as an example, may differ
from the approach for a disease such as sarcoidosis.
Accordingly, when data were available to support a state-
ment, we have endeavored to indicate if a speciﬁc entity
should inﬂuence clinical decision making. We further
recognize that regional differences such as the prevalence of
tuberculosis should inﬂuence clinical advice. Although we
consider a recurrence an indicator of severity, we
acknowledge that the nature of the uveitis disease, associ-
ated systemic disease, and frequency of recurrence are all
important in any decision to initiate NCSIT.
A limitation of the program was greater representation
from Western European countries and the United States
compared with Eastern Europe and Asia. In addition, this
was not a full systematic or Cochrane review, and the level
of evidence in some cases was not robust and did not meet
the criteria for inclusion for some therapies analyzed.
Furthermore, some evidence had to be drawn from literature
outside of uveitis treatment or drawn from the expert
opinions, and subsequent consensus around those opinions
was provided by the experts involved in the initiative.Furthermore, the focus of the initiative was NCSIT with
only brief analysis of local, surgical, or other management
approaches. Finally, it should be acknowledged that clinical
practice varies depending on local factors, such as the
availability of medications or demographics of patients;
because this was intended as a global initiative, local
adaptation and application should be considered.
The initiative also has highlighted the lack of random-
ized, prospective studies in NIU in general, and especially
for speciﬁc subsets of uveitis, such as VKH disease or
birdshot chorioretinopathy. In addition, or even as a
consequence, it is not possible to identify which treatment
would be appropriate for which patient. However, the
initiative has identiﬁed clearly the opportunities to collab-
orate with colleagues and to identify optimal methods of
communication and comanagement of patients.
As novel approaches to treatment and management of
patients with NIU are identiﬁed, future opportunities to
update this initiative may be offered, affording the possi-
bility to adapt recommendations to ﬁt local clinical prac-
tices along with the generation of guidelines with greater
speciﬁcity toward different uveitides or speciﬁc medica-
tions. In addition, measuring any improvement in patient
outcomes as a result of these recommendations would
continue to validate the ﬁndings in meeting the aim of the
initiative.References
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